Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

subcutaneous injection

4 posts
SSwitzerland
Prefillable Glass Syringes Market in Switzerland | Report - IndexBox
Read More

Prefillable Glass Syringes Market in Switzerland | Report – IndexBox

  • 2026-04-04
This report is an independent strategic market study that provides a structured, commercially grounded analysis of the market…
RRoche
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Read More

Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?

  • 2026-02-18
Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of…
RRoche
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Read More

European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma

  • 2026-02-18
F. Hoffmann-La Roche Ltd Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular…
RRoche
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Read More

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity

  • 2026-02-15
F. Hoffmann-La Roche Ltd A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of…
Switzerland
www.europesays.com